Delivery Order SPE2DE21D0017-SPE2D625F3VMJ
- Not listed
- Abbott Rapid DX North America LLC, a subsidiary of Abbott Laboratories Inc., was awarded a $15,000 fixed-price delivery order with economic price adjustment for COVID-19 test kits on August 7, 2025, with an ultimate completion date of August 18, 2025. The contract, issued without set-aside designation, is funded by the Defense Logistics Agency Medical Supply Chain and specifies performance at the contractor's facility in Lockhart, Florida. This delivery order represents a continuation of...
- Abbott Rapid DX North America LLC, a subsidiary of Abbott Laboratories Inc., was awarded a delivery order valued at $3,600.00 on September 9, 2025, for COVID-19 test kits under contract 4569386625. The contract utilizes fixed-price pricing with economic price adjustment and has an ultimate completion date of September 18, 2025. Performance will occur in Lockhart, Florida. The award was made without a set-aside designation, indicating open competition. The funding source is the Defense...
- Abbott Rapid DX North America LLC, a subsidiary of Abbott Laboratories Inc., was awarded a delivery order on April 28, 2025, for COVID-19 test kits with a ceiling value of $2,400.00. This fixed-price delivery order with economic price adjustment carries an ultimate completion date of May 7, 2025, and will be performed in Lockhart, Florida. The contract was awarded without a set-aside designation, indicating open competition. The Defense Logistics Agency Medical Supply Chain, operating under...
- Abbott Rapid DX North America LLC, a subsidiary of Abbott Laboratories Inc., was awarded a delivery order valued at $1,005.05 on April 30, 2025, for BinaxNOW COVID-19 antigen cards. This fixed-price contract with economic price adjustment has an ultimate completion date of May 20, 2025, and will be performed in Lockhart, Florida. The contract was awarded without a set-aside designation, indicating full and open competition. Funding originates from the Defense Logistics Agency's Medical Supply...
- Abbott Rapid DX North America LLC, a subsidiary of Abbott Laboratories Inc., received a delivery order valued at $6,030.30 for BinaxNOW COVID-19 antigen test cards on July 31, 2025, with an ultimate completion date of August 21, 2025. The contract, which carries a fixed-price structure with economic price adjustment provisions, was awarded without a set-aside designation, indicating full and open competition. Performance will be executed in Lockhart, Florida, and the contract is funded through...
- Abbott Rapid DX North America LLC, a subsidiary of Abbott Laboratories Inc., has been awarded a delivery order valued at $1,407.07 for BinaxNOW COVID-19 antigen test cards. This fixed-price contract with economic price adjustment was awarded on July 25, 2025, with an ultimate completion date of August 15, 2025, and will be performed in Lockhart, Florida. The award was issued without a set-aside designation, indicating open competition. Funding is provided through the Defense Logistics Agency...
- Abbott Rapid DX North America LLC, a subsidiary of Abbott Laboratories Inc., was awarded a delivery order valued at $1,206.06 on August 22, 2025, for BinaxNOW COVID-19 antigen test cards. This fixed-price contract with economic price adjustment will be performed in Lockhart, Florida, with an ultimate completion date of September 15, 2025. The contract was awarded without a set-aside designation, indicating open competition. The funding source is the Defense Logistics Agency's Medical Supply...
- Abbott Rapid DX North America LLC, a subsidiary of Abbott Laboratories Inc., was awarded a delivery order on August 18, 2025, for BinaxNOW COVID-19 antigen test cards with a ceiling value of $1,206.06. This fixed-price contract with economic price adjustment was funded by the Defense Logistics Agency Medical Supply Chain and will be performed in Lockhart, Florida. The contract represents an open competition award with no set-aside designation and is scheduled for ultimate completion on September...
- Abbott Rapid DX North America LLC, a subsidiary of Abbott Laboratories specializing in medical diagnostics, was awarded a $6,000 fixed-price delivery order for ID NOW COVID-19 virus test kits by the Defense Logistics Agency Medical Supply Chain on September 11, 2025. The delivery order, which has no set-aside designation, indicates open competition and carries an ultimate completion date of September 19, 2025. The performance location is identified as Lockhart, Florida. This award represents a...
- Abbott Rapid DX North America LLC, a subsidiary of Abbott Laboratories Inc., has been awarded a delivery order valued at $4,020.20 for BinaxNOW COVID-19 antigen test cards. The contract was awarded on August 1, 2025, with an ultimate completion date of August 22, 2025, under a fixed-price arrangement with economic price adjustment provisions. The award was issued without a set-aside designation, indicating open competition among qualified vendors. The Defense Logistics Agency Medical Supply...
- SPE2DE21D0017Indefinite Delivery Contract
- SPE2DE21D0017-SPE2D625F3VMJDelivery Order
Abbott Rapid DX North America LLC, a subsidiary of Abbott Laboratories Inc., was awarded a delivery order valued at $1,800.00 on September 18, 2025, for COVID-19 test kits to support the Defense Logistics Agency Medical Supply Chain. The contract, designated as a fixed-price agreement with economic price adjustment provisions, carries an ultimate completion date of September 29, 2025, and will be performed in Lockhart, Florida. No set-aside designation was applied to this award, indicating the contract was competed on a full and open basis. This delivery order represents a continuation of Abbott Rapid DX North America LLC's established role as a critical federal supplier of COVID-19 diagnostic products, including BinaxNOW rapid antigen tests and related medical testing supplies. The company maintains multiple indefinite delivery vehicles across federal healthcare agencies, particularly with the Department of Veterans Affairs and Defense Logistics Agency, demonstrating its sustained capacity to meet federal diagnostic testing requirements. The modest ceiling value reflects the specific quantities of test kits required under this particular task order within the company's broader framework of federal medical supply contracts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 9/18/25 |